eGenesis raised $191 million in a Series D financing led by Lux Capital to advance its lead program for kidney transplant.

Sep 04, 2024•over 1 year ago

Amount Raised

$191 Million

CambridgeBiotechnology

Investors

Parkwood CorporationNatco PharmaceuticalsEisai InnovationDa VitaLeaps By BayerFresenius Medical Care VenturesAlta PartnersFarallon Capital ManagementKhosla VenturesArch VenturesLux Capital

Description

eGenesis, a biotechnology company, announced the close of a $191 million Series D financing to further its lead product candidate, EGEN-2784, into first-in-human studies. The funding will also help advance additional pipeline programs and scale production.

Company Information

Company

eGenesis

Location

300 TECHNOLOGY SQUARE

Cambridge, Massachusetts, United States

About

eGenesis is revolutionizing the field of transplantation with an unparalleled, multiplexed gene editing platform for the development of human-compatible organs, tissues and cells. Harnessing the latest gene-editing techniques, eGenesis’ mission is to solve the global organ shortage crisis by developing a scalable alternative to allotransplantation. eGenesis is reinvigorating the field of xenotransplantation by addressing the key virology and immunology hurdles that have prevented its advancement to date, and is developing commercially-viable products to save and improve the lives of patients who are waiting for an organ transplant.

Related People

2 contacts

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends